longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden 0.5 hours per response...

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Re														
1. Name and Address of Reporting Person * Jenkins John Kenneth				2. Issuer Name and Ticker or Trading Symbol Corbus Pharmaceuticals Holdings, Inc. [CRBP]					5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner					
(Last) (First) (Middle) C/O CORBUS PHARMACEUTICALS HOLDINGS,INC., 500 RIVER RIDGE DRIVE			$\begin{bmatrix} 0 \\ 0 \end{bmatrix}$	3. Date of Earliest Transaction (Month/Day/Year) 05/22/2019					Officer (give t	itle below)	Other	(specify below)	<u> </u>	
(Street) NORWOOD, MA 02062			4	4. If Amendment, Date Original Filed(Month/Day/Year)				_X_ Fo	6. Individual or Joint/Group FilingCheck Applicable Line) _X_Form filed by One Reporting Person _Form filed by More than One Reporting Person					
(City)		(State)	(Zip)	Table I - Non-Derivative Securities Acqu			Acquired, I	ired, Disposed of, or Beneficially Owned						
1.Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Ye			Execution Date, if C		3. Tran Code (Instr. 8	(A	Securities Acquir) or Disposed of (str. 3, 4 and 5)				C F D	wnership	Beneficial Ownership	
						Code	V Amount (A) or (D)		Price				(I) (Instr. 4)	115(1.4)
Reminder: Repo	ort on a separ						in this fo a curren	who respond orm are not rec tly valid OMB ed of, or Benefic	uired to re control nur	spond ui nber.				474 (9-02)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative	3. Transaction	3A. Deemed Execution Date, i	4. Transaci Code	5. Notion of Dispersion of Acq	rrants, umber	in this for a current ired, Dispos options, con 6. Date Expiration (Month/Date in the current ired)	ed of, or Benefic vertible securitiercisable and Date	uired to re control nur	spond unnber. I Amount	8. Price of		10.	11. Nat p of Indir Benefic e Owners
1. Title of Derivative Security	2. Conversion or Exercise Price of	3. Transaction Date	3A. Deemed Execution Date, i	4. Transaci Code	5. No of E Sector Acquired or E of (I	umber erivative erivative erivative erities uired (A isposed D) r. 3, 4,	in this for a current ired, Dispos options, con 6. Date Expiration (Month/Date in the current ired)	ed of, or Benefic vertible securitiercisable and Date	cially Owned es) 7. Title and of Underlyi Securities	spond unnber. I Amount	8. Price of Derivative Security	9. Number of Derivative Securities Beneficially	10. Ownershi Form of Derivativ Security: Direct (D or Indirec	11. Nat p of Indir Benefic e Owners (Instr. 4
1. Title of Derivative Security	2. Conversion or Exercise Price of Derivative	3. Transaction Date	3A. Deemed Execution Date, i	4. Transaci Code	5. Notion of E Secution Acquired or E of (I	rrants, umber erivative prities uired (A isposed D) r. 3, 4, 5)	in this for a current ired, Dispose ptions, con 6. Date Ex Expiration (Month/D:	ed of, or Benefic vertible securiti ercisable and Date ny/Year)	cially Owned es) 7. Title and of Underlyi Securities	spond unnber. I Amount	8. Price of Derivative Security	9. Number of Derivative Securities Beneficially Owned Following Reported	10. Ownershi Form of Derivativ Security: Direct (D or Indirec	11. Nat p of Indir Benefic Owners (Instr. 4

Reporting Owners

	Relationships				
Reporting Owner Name / Address	Director	10% Owner	Officer	Other	
Jenkins John Kenneth C/O CORBUS PHARMACEUTICALS HOLDINGS,INC. 500 RIVER RIDGE DRIVE NORWOOD, MA 02062	X				

Signatures

/s/ John Jenkins, by Sean Moran, attorney in fact	06/28/2019
**Signature of Reporting Person	Date

Explanation of Responses:

- If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- The option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. The option will vest in equal monthly installments over the course of 12 months beginning on the date of grant.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not re-	equired to respond unless the form displays a currently valid OMB number.